NASDAQ: MAZE
Maze Therapeutics, Inc.
Healthcare · Biotechnology
Market Cap
$1.49B
52w High
$53.65
52w Low
$8.25
P/E
-11.86
Volume
767.58K
Outstanding Shares
55.25M
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 173.43% over the last year. Revenue declined 88.06% over the trailing twelve months. Operating margin moved from 29.97% to -670.26%. Free cash flow declined 277.74% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at -670.26%. A decisive move in revenue — currently down 88.06% — would be the clearest signal to resolve the ambiguity.
Company profile
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States.
Valuation
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
6
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Aug 11, 2026
Q3 FY26 · EPS est -$0.71 · Revenue est $3.11M
View